At the news
? BEARISHIMPACT 7/10 424B5 filed Apr 27, 2026 at 17:22 ET
Oruka Therapeutics filed two preliminary prospectus supplements for a combined equity offering of at least $500 million (plus $75 million overallotment) under its $1 billion shelf registration. The company estimates $496 million cash on hand as of March 31, 2026, and intends to use proceeds for general corporate purposes including R&D and working capital. The substantial dilution from this large follow-on offering is bearish for the stock.
- Offering $500,000,000 of common stock and pre-funded warrants, plus underwriter option for $75,000,000 additional shares
- Second concurrent common stock offering of undisclosed amount (placeholder $[] )
- Cash, cash equivalents, and investments approximately $496 million as of March 31, 2026
- Historical net tangible book value of $471.9 million ($9.69 per share) as of December 31, 2025
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access